259 related articles for article (PubMed ID: 25648332)
1. Calibration weighted estimation of semiparametric transformation models for two-phase sampling.
Fong Y; Gilbert P
Stat Med; 2015 May; 34(10):1695-707. PubMed ID: 25648332
[TBL] [Abstract][Full Text] [Related]
2. Hypothesis tests for stratified mark-specific proportional hazards models with missing covariates, with application to HIV vaccine efficacy trials.
Sun Y; Qi L; Yang G; Gilbert PB
Biom J; 2018 May; 60(3):516-536. PubMed ID: 29488249
[TBL] [Abstract][Full Text] [Related]
3. Analysis of two-phase sampling data with semiparametric additive hazards models.
Sun Y; Qian X; Shou Q; Gilbert PB
Lifetime Data Anal; 2017 Jul; 23(3):377-399. PubMed ID: 26995733
[TBL] [Abstract][Full Text] [Related]
4. Optimal auxiliary-covariate-based two-phase sampling design for semiparametric efficient estimation of a mean or mean difference, with application to clinical trials.
Gilbert PB; Yu X; Rotnitzky A
Stat Med; 2014 Mar; 33(6):901-17. PubMed ID: 24123289
[TBL] [Abstract][Full Text] [Related]
5. Weighted likelihood method for grouped survival data in case-cohort studies with application to HIV vaccine trials.
Li Z; Gilbert P; Nan B
Biometrics; 2008 Dec; 64(4):1247-55. PubMed ID: 19032178
[TBL] [Abstract][Full Text] [Related]
6. Challenges in the development of an HIV-1 vaccine.
Barouch DH
Nature; 2008 Oct; 455(7213):613-9. PubMed ID: 18833271
[TBL] [Abstract][Full Text] [Related]
7. Combining biomarkers for classification with covariate adjustment.
Kim S; Huang Y
Stat Med; 2017 Jul; 36(15):2347-2362. PubMed ID: 28276080
[TBL] [Abstract][Full Text] [Related]
8. Simulation studies of phase III clinical trials to test the efficacy of a candidate HIV-1 vaccine.
Desai KN; Boily MC; Masse BR; Alary M; Anderson RM
Epidemiol Infect; 1999 Aug; 123(1):65-88. PubMed ID: 10487643
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic vaccine trails in Thailand.
Churdboonchart V
J HIV Ther; 2004 Sep; 9(3):57-9. PubMed ID: 15534562
[TBL] [Abstract][Full Text] [Related]
10. Adaptive design: estimation and inference with censored data in a semiparametric model.
Shen Y; Cheng Y
Biostatistics; 2007 Apr; 8(2):306-22. PubMed ID: 16787996
[TBL] [Abstract][Full Text] [Related]
11. Support for the RV144 HIV vaccine trial.
AIDS Vaccine Advocacy Coalition
Science; 2004 Jul; 305(5681):177-80; author reply 177-80. PubMed ID: 15250069
[No Abstract] [Full Text] [Related]
12. Semiparametric additive time-varying coefficients model for longitudinal data with censored time origin.
Sun Y; Shou Q; Gilbert PB; Heng F; Qian X
Biometrics; 2023 Jun; 79(2):695-710. PubMed ID: 34877661
[TBL] [Abstract][Full Text] [Related]
13. Measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV-1 vaccines.
Longini IM; Datta S; Halloran ME
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Dec; 13(5):440-7. PubMed ID: 8970471
[TBL] [Abstract][Full Text] [Related]
14. Mark-specific hazard ratio model with multivariate continuous marks: an application to vaccine efficacy.
Juraska M; Gilbert PB
Biometrics; 2013 Jun; 69(2):328-37. PubMed ID: 23421613
[TBL] [Abstract][Full Text] [Related]
15. Support for the RV144 HIV vaccine trial.
Belshe R; Franchini G; Girard MP; Gotch F; Kaleebu P; Marthas ML; McChesney MB; McCullough R; Mhalu F; Salmon-Ceron D; Sekaly RP; van Rompay K; Verrier B; Wahren B; Weissenbacher M
Science; 2004 Jul; 305(5681):177-80; author reply 177-80. PubMed ID: 15247455
[No Abstract] [Full Text] [Related]
16. Mark-specific proportional hazards model with multivariate continuous marks and its application to HIV vaccine efficacy trials.
Sun Y; Li M; Gilbert PB
Biostatistics; 2013 Jan; 14(1):60-74. PubMed ID: 22764174
[TBL] [Abstract][Full Text] [Related]
17. Best linear inverse probability weighted estimation for two-phase designs and missing covariate regression.
Wang CY; Dai J
Stat Med; 2019 Jul; 38(15):2783-2796. PubMed ID: 30908669
[TBL] [Abstract][Full Text] [Related]
18. Semiparametric analysis of incomplete current status outcome data under transformation models.
Wen CC; Chen YH
Biometrics; 2014 Jun; 70(2):335-45. PubMed ID: 24571634
[TBL] [Abstract][Full Text] [Related]
19. Augmented HIV vaccine trial design for estimating reduction in infectiousness and protective efficacy.
Datta S; Halloran ME; Longini IM
Stat Med; 1998 Jan; 17(2):185-200. PubMed ID: 9483728
[TBL] [Abstract][Full Text] [Related]
20. Regression calibration in semiparametric accelerated failure time models.
Yu M; Nan B
Biometrics; 2010 Jun; 66(2):405-14. PubMed ID: 19645700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
